Drug
sublingual immunotherapy
sublingual immunotherapy is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Phase Distribution
Ph phase_4
1
14%
Ph not_applicable
1
14%
Ph phase_1
1
14%
Ph phase_3
3
43%
Ph phase_2
1
14%
Phase Distribution
1
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
7
all time
Status Distribution
Completed(6)
Other(1)
Detailed Status
Completed6
unknown1
Development Timeline
Analytics
Development Status
Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 33 (42.9%)
Phase 41 (14.3%)
N/A1 (14.3%)
Trials by Status
completed686%
unknown114%
Recent Activity
0 active trials
Showing 5 of 7
completedphase_3
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy
NCT04813380
unknownphase_3
Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children
NCT04851860
completednot_applicable
Immunotherapy for Peanut Allergy
NCT00429429
completedphase_1
Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies
NCT01529437
completedphase_3
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
NCT00310466
Clinical Trials (7)
Showing 7 of 7 trials
NCT04813380Phase 3
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy
NCT04851860Phase 3
Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children
NCT00429429Not Applicable
Immunotherapy for Peanut Allergy
NCT01529437Phase 1
Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies
NCT00310466Phase 3
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
NCT00932607Phase 2
SUBLIVAC® Birch PROBE Study
NCT01127035Phase 4
Sublingual Immunotherapy In Alternaria-Induced Rhinitis
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7